147 related articles for article (PubMed ID: 25137170)
1. [Treatment with urea as an alternative to tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone].
Gómez Valbuena I; Alonso Pérez L; Alioto D; Cañamares Orbis I; Ferrari Piquero JM
Farm Hosp; 2014 Jul; 38(4):379-80. PubMed ID: 25137170
[TBL] [Abstract][Full Text] [Related]
2. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).
Harbeck B; Lindner U; Haas CS
Endocrine; 2016 Sep; 53(3):872-3. PubMed ID: 26961548
[No Abstract] [Full Text] [Related]
3. Urea is successful in treating inappropriate antidiuretic hormone secretion in an infant.
Dufek S; Booth C; Carroll A; Van't Hoff W; Kleta R; Bockenhauer D
Acta Paediatr; 2017 Mar; 106(3):513-515. PubMed ID: 27935121
[No Abstract] [Full Text] [Related]
4. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
Sánchez Sobrino P; Fernández Catalina P; Lorenzo Solar M; Rego Iraeta A
Med Clin (Barc); 2015 Aug; 145(3):138-9. PubMed ID: 25543222
[No Abstract] [Full Text] [Related]
5. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide.
Decaux G
Am J Med; 2001 May; 110(7):582-4. PubMed ID: 11343672
[No Abstract] [Full Text] [Related]
6. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
Mali P; Muduganti SR; Mujibur R; Murali N
WMJ; 2015 Apr; 114(2):66-8. PubMed ID: 26756059
[TBL] [Abstract][Full Text] [Related]
7. Uric acid levels with tolvaptan treatment for syndrome of inappropriate antidiuretic hormone secretion.
Nagamine T
Endocrine; 2024 Mar; 83(3):826-827. PubMed ID: 37982946
[No Abstract] [Full Text] [Related]
8. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light chain multiple mieloma. Treatment with tolvaptan.
Carreño A; Hernández B; Mayoralas Á; Calle C
Nefrologia; 2017; 37(5):558-559. PubMed ID: 28946972
[No Abstract] [Full Text] [Related]
9. What is the role of vaptans in routine clinical nephrology?
Bichet DG
Clin J Am Soc Nephrol; 2012 May; 7(5):700-3. PubMed ID: 22516285
[No Abstract] [Full Text] [Related]
10. [Tolvaptan in antidiuretic hormone secretion syndrome secondary to treatment with citalopram].
Pinal-Fernández I; Segura-García A
Rev Clin Esp; 2011 Oct; 211(9):491-2. PubMed ID: 21531406
[No Abstract] [Full Text] [Related]
11. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostics and new treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH)].
Trolle C; Rittig S; Frøkjær J; Jørgensen JO
Ugeskr Laeger; 2012 Apr; 174(15):1019-22. PubMed ID: 22487409
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion.
Perelló-Camacho E; Pomares-Gómez FJ; López-Penabad L; Mirete-López RM; Pinedo-Esteban MR; Domínguez-Escribano JR
Sci Rep; 2022 Jun; 12(1):10266. PubMed ID: 35715573
[TBL] [Abstract][Full Text] [Related]
14. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
[TBL] [Abstract][Full Text] [Related]
16. Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug.
Graziani G; Cucchiari D; Aroldi A; Angelini C; Gaetani P; Selmi C
J Neurol Neurosurg Psychiatry; 2012 May; 83(5):510-2. PubMed ID: 22323742
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion restriction due to syndrome of inappropriate secretion of ADH after polytrauma.
Kraayvanger L; Latza J; Vockelmann C; Berlit P; Weber R
J Neurol; 2014 Jul; 261(7):1436-8. PubMed ID: 24859331
[No Abstract] [Full Text] [Related]
18. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
19. [SIADH and vaptans].
Decaux G
Ann Endocrinol (Paris); 2012 Apr; 73(2):130-4. PubMed ID: 22537510
[TBL] [Abstract][Full Text] [Related]
20. Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland.
Reinke LM; Seoudy AK; Gärtner F; Rohmann N; Schulte DM; Schreiber S; Jansen O; Laudes M
Exp Clin Endocrinol Diabetes; 2023 Sep; 131(9):472-475. PubMed ID: 37364592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
